ReviewFrontiers in oncology2026
Natural product-induced apoptosis in oral squamous cell carcinoma via targeting mitochondrial multifunctionality.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mitochondria, as the regulatory center of cellular energy metabolism, can influence ATP synthesis, redox balance, and apoptotic pathways. Recent studies have confirmed that some natural products, due to their self-assembling properties and multi-target effects, can inhibit OSCC progression by regulating mitochondrial function, providing key lead compounds for the development of new OSCC therapies. Methods: We retrieved data from PubMed, Embase, Web of Science, and CNKI to classify and summarize the relationship between mitochondria and OSCC, as well as the regulatory mechanisms of natural products. Results: Natural products exhibit unique advantages in inducing apoptosis in OSCC cells through multi-pathway regulation mechanisms targeting mitochondria. Various active components, such as betaine and Arglabin, induce oxidative stress by promoting ROS accumulation, disrupting mitochondrial redox balance, and thereby activating the intrinsic apoptotic pathway; extracts like cantharidin and berberine induce changes in mitochondrial membrane permeability by regulating the expression ratio of Bcl-2 family proteins, promoting the release of Cyt-c and activating the caspase cascade. It is noteworthy that combining radiotherapy drugs with natural products for OSCC treatment offers greater stability without additive side effects. Moreover, nanodelivery technology, through the design of smart responsive carriers, introduces a competitive release mechanism, achieving precise, on-demand drug release at tumor sites, providing important candidates for the development of new antitumor drugs. Conclusion: Natural products targeting mitochondria provide a new direction for the treatment of OSCC, and their potential for clinical translation is expected to overcome existing therapeutic challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.